VVY Vivoryon Therapeut

Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting

Halle (Saale) / Munich, Germany, June 21, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon, or the Company), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, held its Annual General Meeting (AGM) today at 1:00 p.m. (CEST). The shareholders approved all items on the agenda of the meeting.

All documents relating to the AGM, including the presentation of the management of Vivoryon, are available on the Company’s website: https://www.vivoryon.com/ordinary-general-meeting-of-shareholders/2024-annual-general-meeting/.

###

About Vivoryon Therapeutics N.V.

Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by its passion for ground-breaking science and innovation, the Company strives to change the lives of patients in need suffering from severe diseases. The Company leverages its in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. The Company has established a pipeline of orally available small molecule inhibitors for various indications including Alzheimer’s disease, inflammatory and fibrotic disorders, including of the kidney, and cancer. www.vivoryon.com.

Vivoryon Forward Looking Statements

This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.

For more information, please contact:

Investor ContactVivoryon Therapeutics N.V.Dr. Manuela Bader, Director IR & CommunicationTel: +49 (0)345 555 99 30Email: IR@vivoryon.com

Media ContactTrophic CommunicationsValeria FisherTel: +49 175 8041816Email: vivoryon@trophic.eu

Attachment

• 24-06-21_2024 AGM Results_final

Vivoryon Therapeut (EU:VVY)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024

Vivoryon Therapeut (EU:VVY)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024